Characteristics of Iranian women seeking drug treatment

Journal of Women's Health

Volumn 20, Issue 11, 2011, Pages 1687-1691

  Dolan, Kate ^a   Salimi, Shabnam ^b   Nassirimanesh, Bijan ^c   Mohsenifar, Setareh ^b   Allsop, David ^a   Mokri, Azarakhsh ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Persepolis Centre   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; CANNABIS; DIAMORPHINE; METHADONE; MORPHINE; OPIATE;

ALCOHOL CONSUMPTION; ANXIETY; ARTICLE; BLOOD SAMPLING; CANNABIS SMOKING; DEMOGRAPHY; DEPRESSION; DRUG USE; FEMALE; HEALTH; HEPATITIS C VIRUS; HEROIN DEPENDENCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; IRAN; MAJOR CLINICAL STUDY; METHADONE TREATMENT; OPIATE ADDICTION; PRIORITY JOURNAL; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; SOCIAL STATUS; URINALYSIS; WITHDRAWAL SYNDROME;

ADOLESCENT; ADULT; ANALYSIS OF VARIANCE; FEMALE; HEALTH STATUS; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERVIEWS AS TOPIC; IRAN; METHADONE; MIDDLE AGED; OPIATE SUBSTITUTION TREATMENT; OPIOID-RELATED DISORDERS; SEXUALLY TRANSMITTED DISEASES; SUBSTANCE ABUSE TREATMENT CENTERS; SUBSTANCE-RELATED DISORDERS; YOUNG ADULT;

EID: 81155131835     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2010.2694     Document Type: Article

References (40)

1. Hesse M. Integrated psychological treatment for substance use and co-morbid anxiety or depression vs. treatment for substance use alone. A systematic review of the published literature. BMC Psychiatry 2009;9:6.
2. Ross J, Teesson M, Darke S, et al. The characteristics of heroin users entering treatment: Findings from the Australian Treatment Outcome Study (ATOS). Drug Alcohol Rev 2005;24:411-418.
3. Darke S, Ross J. Polydrug dependence and psychiatric co-morbidity among heroin injectors. Drug Alcohol Depend 1997;48:135-141.
4. Mathers CD, Vos ET, Stevenson CE, Begg SJ. The burden of disease and injury in Australia. Bull WHO 2001;79:1076-1084.
5. Warner-Smith M, Darke S, Day C. Morbidity associated with non-fatal heroin overdose. Addiction 2002;97:963-967.
6. Davoli M, Perucci CA, Rapiti E, et al. A persistent rise in mortality among injection drug users in Rome, 1980 through 1992. Am J Public Health 1997;87:851-853.
7. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
8. Grella CE, Scott CK, Foss MA. Gender differences in longterm drug treatment outcomes in Chicago PETS. J Subst Abuse Treat 2005;28 (Suppl 1):S3-12.
9. Razani N, Mohraz M, Kheirandish P, et al. HIV risk behavior among injection drug users in Tehran, Iran. Addiction 2007;102:1472-1482.
10. Day C, Nassirimanesh B, Shakeshaft A, Dolan K. Patterns of drug use among a sample of drug users and injecting drug users attending a general practice in Iran. Harm Reduct J 2006;3:2.
11. Ghanizadeh A, Ashkani H, Maany I. Comorbidity of psychiatric disorders in Iranian treatment seeking opioid addicts. Iranian J Med Sci 2000;25:25-30.
12. Mokri A. Brief overview of the status of drug abuse in Iran. Arch Iranian Med 2002;5:184-190.
13. Gouya MM. National report on HIV and AIDS cases. In: Disease Management Center MoHaME. Tehran: Islamic Republic of Iran, 2005.
14. Dolan K, Kite B, Black E, et al. HIV in prison in low-income and middle-income countries. Lancet Infect Dis 2007;7:32-41.
15. Ray Kim W. Global epidemiology and burden of hepatitis C. Microbes Infect 2002;4:1219-1225.
16. Rahbar AR, Rooholamini S, Khoshnood K. Prevalence of HIV infection and other blood-borne infections in incarcerated and non-incarcerated injection drug users (IDUs) in Mashhad, Iran. Int J Drug Policy 2004;15:151-155.
17. Razzaghi E, Nassirimanesh B, Afshar P, Ohiri K, Claeson M, Power R. HIV/AIDS harm reduction in Iran. Lancet 2006;368:434-435.
18. Vazirian M, Nassirimanesh B, Zamani S, et al. Needle and syringe sharing practices of injecting drug users participating in an outreach HIV prevention program in Tehran, Iran: A cross-sectional study. Harm Reduct J 2005;2:19.
19. Dolan KA, Salimi S, Nassirimanesh B, Mohsenifar S, Mokri A. The establishment of a methadone treatment clinic for women in Tehran, Iran. J Public Health Policy 2011; 32:219-230.
20. Darke S, Hall W, Wodak A, Heather N, Ward J. Development and validation of a multi-dimensional instrument for assessing outcome of treatment among opiate users: The Opiate Treatment Index. Br J Addict 1992;87:733-742.
21. Beck AT, Rial WY, Rickels K. Short form of depression inventory: Cross-validation. Psychol Rep 1974;34:1184-1186.
22. Beck AT, Steer RA, Carbin MG. Psychometric properties of the Beck Depression Inventory: Twenty-five years of evaluation. Clin Psychol Rev 1988;8:77-100.
23. World Health Organization. ICD-10: International statistical classification of diseases and related health problems. Geneva: WHO, 2004.
24. Goldberg DP. Manual of the General Health Questionnaire. Windsor, U.K.: NFER Publishing, 1978.
25. Dolan KA, Salimi S, Nassirimanesh B, Mohsenifar S, Allsop DJ, Mokri A. HIV and HCV seroincidence among female drug users in Tehran, Iran. Poster presentation at the Australian Society for HIV Medicine. Sydney, 2010.
26. Ramezani Tehrani F, Malek-Afzali H. Knowledge, attitudes and practices concerning HIV/AIDS among Iranian at-risk sub-populations. East Mediterr Health J 2008;14:142-156.
27. Vieweg BW, Hedlund JL. The General Health Questionnaire (GHQ): A comprehensive review. J Operational Psychiatry 1983;14:74-81.
28. Razzaghi EM, Rahim AM, Hosseni M, Madani S, Chatterjee A. Rapid situation assessment (RSA) of drug abuse in Iran (1998-1999). In: Prevention department SWO, Ministry of Health, I.R. of Iran and United Nations International Drug Control Program. Tehran, 1999.
29. Pinkham S, Malinowska-Sempruch K. Women, harm reduction, and HIV. J Reprod Health Matters 2008;16:168-181.
30. Dolan K, Hall W, Wodak A. Methadone maintenance reduces injecting in prison. BMJ 1996;312:1162.
31. Dolan KA, Wodak AD, Hall WD. Methadone maintenance treatment reduces heroin injection in New South Wales prisons. Drug Alcohol Rev 1998;17:153-158.
32. Dolan K, Wodak A, Hall W, Gaughwin M, Rae F. HIV risk behaviour of IDUS before, during and after imprisonment in New South Wales. Addict Res Theory 1996;4:151-160.
33. Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: Mortality, re-incarceration and hepatitis C infection. Addiction 2005;100:820-828.
34. Farnia M, Ebrahimi B, Shams A, Zamani S. Scaling up methadone maintenance treatment for opioid-dependent prisoners in Iran. Int J Drug Policy 2010;21:422-424.
35. Dolan K, Wodak A. An international review of methadone provision in prisons. Addict Res 1996;4(1):85-97.
36. Zamani S, Farnia M, Torknejad A, et al. Patterns of drug use and HIV-related risk behaviors among incarcerated people in a prison in Iran. J Urban Health 2010;87:603-616.
37. McLellan AT, Luborsky L, Woody GE, O'Brien CP, Druley KA. Predicting response to alcohol and drug abuse treatments. Role of psychiatric severity. Arch Gen Psychiatry 1983;40:620-625.
38. Compton WM 3rd, Cottler LB, Jacobs JL, Ben-Abdallah A, Spitznagel EL. The role of psychiatric disorders in predicting drug dependence treatment outcomes. Am J Psychiatry 2003;160:890-895.
39. Mohebbi MR. Female sex workers and fear of stigmatisation. Sex Transm Infect 2006;81:180-181.
40. Meysamie A, Ghaletaki R, Haghazali M, Asgari F, Rashidi A, Khalilzadeh O, Esteghamati A, Abbasi M. Pattern of tobacco use among the Iranian adult population: results of the national survey of Risk Factors of Non-Communicable Diseases (SuRFNCD-2007). Tobacco Control 2010;19:125-128.